Programmable, targeted therapies for ocular oncology
ReBio is advancing a new generation of targeted therapies designed to reach the right site, at the right dose, for the right duration.
Uveal melanoma is the most common eye cancer in adults. Still, no approved therapy exists for primary disease.
Radiation and enucleation lead to vision loss, yet have done little to improve long-term survival outcomes.
ReBio is developing targeted, potent, vision-preserving ocular cancer treatments.
Our proprietary platform, SiSu®, is a therapeutic amplifier. It designs targeted, locally delivered conjugates that enable precise, programmable drug exposure across targets and indications.
RBP-01
Uveal Melanoma
Our lead program, RBP-01, is a SiSu®-conjugated PKC inhibitor delivered via localized intravitreal injection for programmed release and superior ocular retention, achieving high concentrations with minimal off-target exposure.
RBP-02
Retinoblastoma
RBDX
Post-op ocular inflammation
RBLP
Glaucoma
RBP-05
RBP-05
A team translating precision into patient impact
Leaders in organic chemistry, oncology, and drug development redefining what’s possible in ocular oncology.
